Arch Iran Med. 2022;25(9): 617-623.
doi: 10.34172/aim.2022.97
  Abstract View: 146
  PDF Download: 169

Original Article

Clinical Evaluation of an HTK Solution for Liver Transplantation: A Phase 3 Randomized Pilot Clinical Trial Study

Seyed Ali Malekhosseini 1 ORCID logo, Younes Ghasemi 2,3* ORCID logo, Javad Rousta 2, Roghayyeh Aghaei 2, Sedigheh Kianpour 2, Manica Negahdaripour 2,3 ORCID logo, Reza Heidari 2, Alireza Shamsaeefar 1, Siavash Gholami 1, Saman Nikeghbalian 1* ORCID logo

1 Shiraz Transplant Center, Abu Ali Sina Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
2 Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
3 Department of Pharmaceutical Biotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
*Corresponding Authors: Corresponding Author: Younes Ghasemi, PharmD, PhD; Email: , Email: ghasemiy@sums.ac.ir; Corresponding Authors: Saman Nikeghbalian, MD; Email: , Email: shiraz.livertransplantation@gmail.com


Background: Organ preservation solutions are not easily accessible in Iran, similar to many resource-limited countries. We aimed to evaluate the efficacy of a locally-produced HTK solution among adult liver transplantation candidates in a pilot clinical trial study.

Methods: Adult patients undergoing liver transplantation were randomly allocated into two groups. One received the HTK solution (PharMedCina Inc., Shiraz, Iran), and the second received the commercially available HTK solution (Custodiol ®).

Results: Overall, 28 individuals entered the study, including 11 and 9 males (78.6% and 64.3%) in the Custodiol® and local HTK groups, respectively. Clinical characteristics, including postoperative biliary complications, reperfusion syndrome, infection and primary non-function (PNF) rates, amount of intraoperative bleeding, length of hospital and ICU stay, peak aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and duration of follow-up were similar between the two groups (P>0.05). One patient died in the locally-produced HTK group. The patient underwent re-transplantation 20 days after his first liver transplantation due to PNF. Two patients died in the Custodiol group, both due to PNF of the liver, which occurred five and three days after transplantation. The two groups did not show any difference regarding serum levels of AST, ALT, alkaline phosphatase (ALP), bilirubin, platelet count, prothrombin time and international normalized ratio, white blood cell count, blood urea nitrogen, and creatinine on the first postoperative day and on the day of discharge (P>0.05).

Conclusion: Based on the findings of this pilot study with the current sample size, no statistically significant difference was found between our locally-produced HTK solution and Custodiol® regarding clinical outcomes

Cite this article as: Malekhosseini SA, Ghasemi Y, Rousta J, Aghaei R, Kianpour S, Negahdaripour M, et al. Clinical evaluation of an htk solution for liver transplantation: A phase 3 randomized pilot clinical trial study. Arch Iran Med. 2022;25(9):617-623. doi: 10.34172/aim.2022.97
First Name
Last Name
Email Address
Security code

Abstract View: 147

Your browser does not support the canvas element.

PDF Download: 169

Your browser does not support the canvas element.

Submitted: 17 Jul 2021
Revision: 07 Feb 2022
Accepted: 27 Feb 2022
ePublished: 01 Sep 2022
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)